ArticleBMC immunology2025
Combining machine learning with external validation to explore necroptosis and immune response in moyamoya disease.
Article in BMC immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Infections in Moyamoya Phenomenon: Current Evidence and Future Horizons-Narrative Review.International journal of general medicine · 2025Review
- Downregulation of IL-20RA in Cerebrospinal Fluid Associated with the Risk of Moyamoya Disease: A Molecular Signatures Analysis with an Inflammation Proteomics Landscape.Journal of inflammation research · 2025Article
- Post-translational modification gene signatures implicate FBXW7 in immune and vascular dysregulation of Moyamoya disease.Frontiers in genetics · 2025Article
- Deep learning and high-resolution magnetic resonance vascular wall imaging: current challenges and future perspectives.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Moyamoya disease (MMD) is a rare chronic vascular disease leads to cognitive impairment and stroke with its etiology unknown. The relationship between necroptosis or necroinflammation and MMD pathogenesis was poorly understood. Differentially expressed necroinflammation and necroptosis related genes (DE-NiNRGs) were selected based on the public gene expression data from Gene Expression Omnibus (GEO) and validated by our self-test data of MMD patients and control group. Functional enrichment analysis, PPI network and multi-factors regulation network construction of DE-NiNRGs were employed to discover the connections between these genes. DE-NiNRGs and immune cells correlation analysis provided evidence for the relationship between DE-NiNRGs and necroinflammation in MMD patients. We then established an MMD prediction model using support vector machine (SVM) and selected DE-NiNRGs as features. The DE-NiNRGs based MMD prediction model had excellent performance on test set with the area under the curve (AUC) higher than 0.9. Four genes, PTGER3, ANXA1, ID1, and IL1R1, that contributed significantly to the SVM model and passed the test of validation set are key genes in DE-NiNRGs. The upregulation of PTGER3 expression indicated that necroptosis and angiogenesis were promoted in MMD patients, whereas the downregulation of ANXA1 expression indicated that the migration and differentiation of immune cells are closely related to MMD pathogenesis. These findings provided new inspiration for our study of the immune-related pathogenesis and therapeutic targets of MMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.